Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEH1 | O60930 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.33 |
| ▸ | FEN1 | P39748 | 2/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL421827 | 0.80 | RNASEH1 (0.32) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL421826 | 0.80 | RNASEH1 (0.32) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL421825 | 0.80 | RNASEH1 (0.32) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL10144372 | 0.71 | ERCC1 (0.44) | ERCC1FEN1ERCC4 | |
| SCHEMBL417488 | 0.70 | RNASEH1 (0.35) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL417489 | 0.70 | RNASEH1 (0.35) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL417487 | 0.70 | RNASEH1 (0.35) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL420508 | 0.67 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL420507 | 0.67 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4 | |
| SCHEMBL420509 | 0.67 | RNASEH1 (0.43) | RNASEH1ERCC1FEN1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | RNASEH1 315/4885ERCC1 1084/4885FEN1 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.